Examples of 'is bevacizumab' in a sentence
Meaning of "is bevacizumab"
is bevacizumab: Bevacizumab is a medication used to treat various types of cancer by inhibiting the growth of new blood vessels
How to use "is bevacizumab" in a sentence
Basic
Advanced
is bevacizumab
The active substance is bevacizumab.
The anti-VEGF antibody is bevacizumab and the chemotherapeutic is paclitaxel.
The angiogenesis inhibitor is bevacizumab.
The dual-targeting protein of claim 8, wherein the antibody binding specifically to VEGF is Bevacizumab.
In certain embodiments, the anti-VEGF antibody is bevacizumab or a fragment or variant thereof.
An agent for use as claimed in claim 1 wherein said additional therapeutic agent is bevacizumab.
A preferred antibody is bevacizumab.
In some embodiments the anti-VEGF antibody used in the methods of the invention is bevacizumab.
More preferably the anti-VEGF antibody is bevacizumab or ranibizumab.
The pharmaceutical composition of example D1, wherein the antibody is bevacizumab.
In a further aspect, the VEGF inhibitor is bevacizumab or ranibizumab.
In some embodiments, the anti-VEGF therapeutic agent is bevacizumab.
In some variations, the anti-VEGF antibody is bevacizumab ( such as Avastin ® ).
Most preferably, the anti-VEGF antibody of the invention is bevacizumab.
In some examples, the anti-VEGF antibody is bevacizumab ( such as Avastin ® ).
See also
In one such embodiment, the anti-angiogenic agent is bevacizumab.
An exemplary VEGF antagonist is Bevacizumab ( Avastin ™ ).
The method of claim 8, wherein said anti-VEGF antibody is bevacizumab.
In some embodiments, the anti-VEGF antibody is bevacizumab ( such as Avastin ® ).
Use according to claim 1 or claim 2, characterized in that said anti-VEGF antibody is bevacizumab.
One example of a VEGFR antibody is bevacizumab ( AVASTIN ® ).
The anti-VEGF antibody for use of claim 1, wherein the anti-VEGF antibody is bevacizumab.
In one embodiment, the antibody is bevacizumab.
While a number of angiogenesis inhibitors are known, the most prominent angiogenesis inhibitor is bevacizumab ( Avastin ® ).
Preferably, the VEGF antibody is bevacizumab.
The method of example G22, wherein the additional therapeutic agent is bevacizumab.
In a preferred embodiment, the anti-angiogenic therapy is bevacizumab ( Avastin ® ).
A method according to embodiment 141, wherein the FcR binding peptide is bevacizumab.
A specific example of an anti-VEGF antibody is bevacizumab.
In certain embodiments, the therapeutic agent is bevacizumab.
In some embodiments the anti-VEGF antibody is bevacizumab.
The method of clause 16 wherein the antibody is bevacizumab.
In certain embodiments, the anti-VEGF antibody is bevacizumab.
In some embodiments, the anti-angiogenic agent is bevacizumab.
The method of claim 13 wherein the antibody is bevacizumab.
In another embodiment, the anti-VEGF antibody is bevacizumab.
The method of example E1, wherein the antibody is bevacizumab.
The method of claim 1 or claim 2, wherein the anti-VEGF antibody is bevacizumab.
The anti-VEGF antibody of claim 1, wherein the anti-VEGF antibody is bevacizumab.
The anti-VEGF antibody for use according to any one of claims 12 to 21, which is bevacizumab.
The antibody for the use of claim 13 or 14, wherein said second therapeutic antibody is bevacizumab.
You'll also be interested in:
Examples of using Bevacizumab
Show more
Bevacizumab may only be available in some situations
It rarely resulted in discontinuation of bevacizumab treatment or hospitalisation
One particularly preferred combination includes bevacizumab
